Inj givosiran 0.5 mg
Products billed under this code include Givlaari.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Givlaari.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Givlaari | Alnylam Pharmaceuticals, Inc. | 71336-1001-01 | 378 | $45,641.232 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $120.744 | −$0.171 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted September 17, 2026 |
| 3Q26 | $120.915 | −$0.068 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted September 15, 2026 |
| 2Q26 | $120.983 | +$0.298 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted September 15, 2026 |
| 1Q26 | $120.685 | +$3.325 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted September 15, 2026 |
| 4Q25 | $117.36 | +$0.17 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted September 8, 2026 |
| 3Q25 | $117.19 | +$0.719 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted March 10, 2026 |
| 2Q25 | $116.471 | +$1.005 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted March 10, 2026 |
| 1Q25 | $115.466 | +$3.331 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted December 19, 2025 |
| 4Q24 | $112.135 | −$0.144 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted June 11, 2025 |
| 3Q24 | $112.279 | +$0.259 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted June 11, 2025 |
| 2Q24 | $112.02 | −$0.06 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted March 11, 2025 |
| 1Q24 | $112.08 | −$0.016 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted December 19, 2024 |
| 4Q23 | $112.096 | −$0.39 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted October 10, 2024 |
| 3Q23 | $112.486 | +$2.755 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted June 5, 2024 |
| 2Q23 | $109.731 | −$0.086 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted February 23, 2024 |
| 1Q23 | $109.817 | −$0.063 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted December 6, 2023 |
| 4Q22 | $109.88 | +$1.921 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted June 22, 2023 |
| 3Q22 | $107.959 | +$1.301 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted June 9, 2023 |
| 2Q22 | $106.658 | −$0.009 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted December 14, 2022 |
| 1Q22 | $106.667 | −$0.093 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted June 8, 2022 |
| 4Q21 | $106.76 | +$0.004 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted June 2, 2022 |
| 3Q21 | $106.756 | −$0.023 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted June 2, 2022 |
| 2Q21 | $106.779 | −$0.101 | 0.5 MG | Inj givosiran 0.5 mg | v1, posted March 1, 2022 |
| 1Q21 | $106.88 | – | 0.5 MG | Inj givosiran 0.5 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.